Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.
Saudi J Gastroenterol · 2010
Last updated 2026-05-28In a study on diabetic rats, kidney injury led to worse liver damage compared to non-diabetic rats. Giving the GLP-1 drug exenatide for 14 days before the injury reduced markers of liver damage and improved antioxidant levels in the liver.
AI summary of the abstract below.
| Journal | Saudi J Gastroenterol, 2010 |
|---|---|
| Citations | 29 |
| Relative citation ratio | 0.91 |
| NIH percentile | 47 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
BACKGROUND/AIM: This study was designed to investigate the possible effect of exenatide (Glucagon like Peptide-1 receptor agonist) on liver injury (distant organ) induced by renal ischemia reperfusion (IR) in diabetic rats.
MATERIALS AND METHODS: In vivo renal IR was performed in both type 2 diabetic and normal rats. Each protocol comprised ischemia for 30 minutes followed by reperfusion for 24 hours and a treatment period of 14 days before induction of ischemia.
RESULTS: Lipid peroxidation, xanthine oxidase activity, myeloperoxidase activity and nitric oxide level in liver tissue were significantly increased (P < 0.01, P < 0.001, P < 0.001, P < 0.05, respectively), after IR in diabetic rats compared to normal rats. Antioxidant enzymes like glutathione, superoxide dismutase, catalase and glutathione peroxidase were significantly reduced (P < 0.05, P < 0.05, P < 0.01, P < 0.05, respectively), after IR in diabetic rats compared to normal rats. Exenatide treatment significantly normalized (P < 0.01), these biochemical parameters in treated rats compared to diabetic IR rats. Serum creatinine phosphokinase activity and liver function enzymes were also significantly normalized (P < 0.001, P < 0.001, respectively), after administration of exenatide.
CONCLUSION: Exenatide exerted protective effect on exaggerated remote organ (liver) injury induced by renal IR in diabetes.
Verbatim abstract via PubMed 20616412 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.